A start-up in China has developed a new pill that it claims could potentially extend the average human lifespan to 150 years. Lonvi Biosciences asserts that their innovative formula targets ‘zombie cells’ in the body, which are aging cells that linger and contribute to inflammation and age-related ailments.
The Shenzhen-based company, led by CEO Ip Zhu, proudly describes the pill as more than just a typical medication, labeling it as the “Holy Grail.” The key ingredient of the pill is sourced from grape seeds and has demonstrated the ability to prolong lifespans in laboratory animals by delaying age-related diseases.
Researchers at Lonvi Biosciences believe that taking the pill could enable individuals to live beyond 120 years, with the potential for surpassing the 150-year mark if taken from an early age. The pill’s main component, procyanidin C1 (PCC1), derived from grape seeds, has shown promising results in mouse trials, increasing overall lifespan by 9.4% and providing a remarkable 64% extension from the first dose.
Lyu Qinghua, the chief technology officer at Lonvi, expressed confidence in the pill’s capabilities, stating that reaching the age of 150 is a realistic goal that could be achieved in the near future. China has prioritized anti-aging research, with President Xi Jinping discussing the topic with Russian President Vladimir Putin. The country has integrated anti-aging research with artificial intelligence and biotechnology, leading to a significant advancement in longevity studies.
The field has garnered increased interest and investment, with various entrepreneurs joining the race. Lonvi emphasizes that their PCC1 capsule aims not only to extend lifespan but also to enhance quality of life by slowing down the effects of aging. Although the research has not yet progressed beyond the laboratory stage, with no human trials conducted to validate the claims, the potential for groundbreaking advancements in longevity science is evident.